Osteomyelofibrose
Osteomyelofibrose ist eine Knochemarkerkrankung bei der es zu einer übermäßigen Fibrosierung des Knochenmarkes kommt. Das Knochenmark wird von fibrotischem Narbengewebe verdrängt. Die Erkrankung kann durch somatische Mutationen im JAK2-Gen hervorgerufen werden.
Gliederung
Referenzen:
| 1. |
Baxter EJ et. al. () Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. [^] |
| 2. |
Kralovics R et. al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. [^] |
| 3. |
Méndez-Ferrer S et. al. (2008) Haematopoietic stem cell release is regulated by circadian oscillations. [^] |
| 4. |
Méndez-Ferrer S et. al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. [^] |
| 5. |
Arranz L et. al. (2014) Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. [^] |
| 6. |
Delhommeau F et. al. (2009) Mutation in TET2 in myeloid cancers. [^] |
| 7. |
Sieff CA et. al. (1980) Familial myelofibrosis. [^] |
| 8. |
Bonduel M et. al. (1998) Familial idiopathic myelofibrosis and multiple hemangiomas. [^] |
| 9. |
Pikman Y et. al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. [^] |
| 10. |
Pardanani AD et. al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. [^] |
| 11. |
Kaufmann KB et. al. (2012) A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. [^] |
| 12. |
Jutzi JS et. al. (2013) MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. [^] |
| 13. |
Cazzola M et. al. (2014) JAK inhibitor in CALR-mutant myelofibrosis. [^] |
| 14. |
Passamonti F et. al. (2014) JAK inhibitor in CALR-mutant myelofibrosis. [^] |
| 15. |
Cassinat B et. al. (2014) Interferon alfa therapy in CALR-mutated essential thrombocythemia. [^] |
